



# **Asia-Pacific consensus**

## Utility of PIVKA-II in HCC surveillance and monitoring

This material is intended for use  
by healthcare professionals.

# The first Asia-Pacific consensus statement on PIVKA-II in HCC

## Background



Drafted by **17 leading experts** in HCC from **10 regions** across Asia Pacific:<sup>1</sup>

- China
- Indonesia
- Malaysia
- South Korea
- Thailand
- Hong Kong
- Japan
- Singapore
- Taiwan
- Vietnam



Presented at the **APASL meeting** in Seoul, Korea 2022




Published in the **Clinical and Molecular Hepatology journal** in 2023

## Six consensus statements on the clinical value of PIVKA-II in HCC detection and treatment monitoring were reached with strong levels of agreement

### Agreement




PIVKA-II in combination with AFP **improves the detection of HCC, including small-sized tumors ( $\leq 3$  cm)**, compared to either biomarker alone



PIVKA-II is valuable in the **detection of HCC in AFP-negative HCC patients**




Perioperative PIVKA-II measurement **predicts the MVI risk**, which may be useful in the assessment of tumor prognosis




PIVKA-II measurements, before and after curative treatment (resection and RFA), are useful for **monitoring treatment outcomes and recurrence**



PIVKA-II measurements, before and after intra-arterial treatment (TACE and TARE), are **clinically useful to indicate response**




Pre-liver transplant PIVKA-II levels are associated with the risk of post-operative HCC recurrence, potentially **facilitating patient selection**




# Experts agreed on the use of PIVKA-II as an aid in diagnosis of HCC

PIVKA-II in combination with AFP improves the detection of HCC, including small-sized tumors ( $\leq 3$  cm), compared to either biomarker alone



## PIVKA-II is valuable in the detection of HCC in AFP-negative HCC patients



## Experts agreed that PIVKA-II is valuable in:



**References:**

1. Kim DY et al. *Clin Mol Hepatol* 2023. doi: 10.3350/cmh.2022.0212. Epub ahead of print.
2. Chen H et al. *Oncotarget* 2017;8:90390–401.
3. Xu F et al. *Dis Markers* 2021;2021:8868370.
4. El-Serag HB et al. *Therap Adv Gastroenterol* 2011;4:5–10.
5. Kao WY et al. *Medicine* 2015;94:e1929.
6. Farinati F et al. *Am J Gastroenterol* 2006;101:524–32.
7. Ji J et al. *PLoS One* 2016;11:e0153227.

**Abbreviations:**

AFP, alpha fetoprotein; APASL, Asian Pacific Association for the Study of the Liver; AUC, area under the curve; HCC, hepatocellular carcinoma; MVI, microvascular invasion; PIVKA-II, Protein Induced by Vitamin K Absence or antagonist-II; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; TARE, transarterial radioembolization.